SECONDARY ACUTE MYELOID LEUKEMIA

This study tested a combination of two drugs, azacitidine and gemtuzumab ozogamicin, in 133 adults aged 60 and older with untreated acute myeloid leukemia (AML). The goal was to see if the combination could safely lead to complete remission. Participants received the drugs as ini…

This early-stage study tests the safety and best dose of a targeted radiation therapy (TMLI) combined with two chemotherapy drugs before a donor stem cell transplant. It includes 36 people with high-risk acute leukemia or myelodysplastic syndrome (MDS). The goal is to prepare the…

This study tests whether adding a drug called decitabine to standard chemotherapy can help more people with acute myeloid leukemia (AML) achieve remission. About 178 adults with less favorable types of AML will receive either low or high dose decitabine alongside chemo. The goal …

This early-phase trial tests a new drug called navtemadlin (KRT-232) combined with two standard drugs (decitabine and venetoclax) for people with acute myeloid leukemia (AML) that has come back, not responded to treatment, or is newly diagnosed. The main goal is to find the safes…

This early-phase study tests a combination of two drugs—ipilimumab (an immunotherapy that helps the immune system attack cancer) and decitabine (a chemotherapy drug)—in people with myelodysplastic syndrome or acute myeloid leukemia that has returned or not responded to prior trea…

This study tests whether adding an immunotherapy drug (pembrolizumab) to standard chemotherapy (azacitidine and venetoclax) can improve outcomes for older adults with newly diagnosed acute myeloid leukemia (AML) who cannot have intensive chemo. About 60 participants will be rando…

This study tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy can better eliminate leftover cancer cells in adults newly diagnosed with acute myeloid leukemia (AML). About 49 participants receive either chemo alone or chemo plus pembrolizumab. The …

This early-phase study tested a combination of three drugs—bortezomib, sorafenib, and decitabine—in 15 adults with acute myeloid leukemia (AML), including older patients or those whose cancer returned. The main goal was to find the safest dose and check for side effects. Research…

This study tests a modified plan to prevent and treat cytomegalovirus (CMV) infection in people with blood cancers who have had a donor stem cell transplant. CMV is a common virus that can cause serious problems after transplant. The study involves 153 participants and looks at w…

This study tests a chemotherapy drug called CPX-351 in people under 60 with secondary acute myeloid leukemia (AML), a type of leukemia that develops after other blood disorders or cancer treatments. The goal is to see how well the drug can make the cancer disappear or improve blo…

This early-stage study tests a new antibody drug called Hu8F4 in 72 people with advanced blood cancers like leukemia and myelodysplastic syndrome. The main goals are to find the safest dose and check for side effects. Researchers hope the antibody can stop cancer cells from growi…

This early-phase study tests a new type of immunotherapy for people with acute myeloid leukemia (AML) or blastic plasmacytoid dendritic cell neoplasm (BPDCN) that has come back or not responded to standard treatments. The therapy uses a patient's own or a donor's immune cells, wh…

This study looks at whether cognitive behavioral therapy (CBT) can help adults with acute myeloid leukemia or lymphoma who feel very tired from their cancer or treatment. Participants will attend up to 7 counseling sessions to learn skills to cope with fatigue, anxiety, and depre…